EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease

Louisa Warryn, Gerd Pluschke

CHIMIA · 2023

DOI: 10.2533/chimia.2023.577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHIMIA, 2023. Verfasst von Louisa Warryn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland. Louisa.Warryn@swisstph.ch. Hauptthemen laut MEDLINE: Mycobacterium ulcerans, Tuberculosis, Buruli Ulcer. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Botnar Research Centre for Child Health, University of Basel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Buruli ulcer (BU) is a chronic necrotizing skin disease caused by Mycobacterium ulcerans. Historically, the disease was treated by surgical excision of the skin lesions, until an 8-week combination therapy of rifampicin and streptomycin was introduced in 2004. This treatment modality was effective and reduced recurrence rates. Rifampicin is the most efficacious antibiotic for the treatment of BU and, should rifampicin-resistant M. ulcerans strains emerge, there is currently no replacement for it. As for mycobacterial diseases in general, there is a pressing need for the development of novel, fast-acting drugs. Under market economy conditions, repurposing of new tuberculosis drug candidates is the most promising avenue for alternative BU treatments. Our drug repurposing activities have led to the identification of several actives against M. ulcerans. In particular, the cytochrome bc1 complex inhibitor telacebec (Q203) is a promising drug candidate for the treatment of BU in Africa and Australia. While an active cytochrome-bd oxidase bypass limits the potency of the cytochrome-bc1-specific inhibitor telacebec against M. tuberculosis, classical lineage M. ulcerans strains rely exclusively on cytochrome-bc1 to respire. Hence, telacebec is effective at nanomolar concentration against M. ulcerans, and a high treatment efficacy in an experimental mouse infection model indicates that treatment of BU could be substantially shortened and simplified by telacebec.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium ulceransTuberculosisBuruli UlcerAnimalsMiceRifampinDrug RepositioningDisease Models, AnimalCytochromes

Stichwörter der Autor:innen

Buruli ulcerDrug repurposingMycobacterium ulceransQ203Telacebec

Substanzen

RifampinCytochromes

Autor:innen und Institutionen

  • Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland. Louisa.Warryn@swisstph.ch.
  • University of Basel, Basel, Switzerland.
  • Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland. Gerd.Pluschke@swisstph.ch.

Förderung

  • Botnar Research Centre for Child Health, University of Basel

Zitieren

APA

Warryn, L., & Pluschke, G. (2023). Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease. CHIMIA. https://doi.org/10.2533/chimia.2023.577

Vancouver

Warryn L, Pluschke G. Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease. CHIMIA. 2023. doi:10.2533/chimia.2023.577

BibTeX
@article{Warryn2023,
  author = {Warryn, Louisa and Pluschke, Gerd},
  title = {Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease},
  journal = {CHIMIA},
  year = {2023},
  doi = {10.2533/chimia.2023.577}
}
Kostenlos starten →